FDA Approves Ixazomib for Relapsed, Refractory Multiple Myeloma

Share this content:
The FDA has approved ixazomib (Ninlaro) in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma.
The FDA has approved ixazomib (Ninlaro) in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma.

The U.S. Food and Drug Administration (FDA) has approved ixazomib (Ninlaro), an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least 1 prior therapy.1

“As we learn more about the underlying biology of multiple myeloma, we are encouraged to see the development of new ways to treat this disease,” said Richard Pazdur, MD, director of the Office of Hematology and Oncology Products in FDA's Center for Drug Evaluation and Research.

Approval was based on the findings from an international, double-blind clinical trial of 722 patients with relapsed and/or refractory multiple myeloma. Participants were randomly assigned to receive ixazomib or placebo in combination with lenalidomide and dexamethasone.

Results showed that median progression-free survival was 20.6 months for the ixazomib group compared with 14.7 months with placebo.

In regard to safety, the most common adverse events of ixazomib were diarrhea, constipation, thrombocytopenia, peripheral neuropathy, nausea, peripheral edema, vomiting, and back pain.

RELATED: Melphalan, ASCT Consolidation Remains Preferred Option in Transplant-eligible Multiple Myeloma

“Today's approval is the third drug for multiple myeloma approved this year and provides patients with a new oral treatment that slows disease progression when other therapy has failed,” Dr. Pazdur said.

The National Cancer Institute estimates that there will be approximately 26 850 new cases of multiple myeloma in the United States in 2015 and about 11 240 multiple myeloma-related deaths.

Reference

  1. FDA approves Ninlaro, new oral medication to treat multiple myeloma [news release]. Silver Spring, MD: U.S. Food and Drug Administration; November 20, 2015. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm473774.htm. Accessed November 20, 2015.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs